Bristol Myers Squibb (BMY) Land & Improvements (2025 - 2026)
Bristol Myers Squibb's (BMY) quarterly Land & Improvements came in at $157.0 million in Q2 2026, little changed quarter-over-quarter from $157.0 million in Q1 2026.
Powered by 
Analysis
Bristol Myers Squibb (BMY) Land & Improvements (2025 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has reported Land & Improvements for 2 consecutive years, with $157.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Land & Improvements changed N/A year-over-year to $157.0 million in Q2 2026; TTM through Jun 2026 was $157.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $157.0 million, changed N/A from the prior year.
- Land & Improvements was $157.0 million for Q2 2026 at Bristol Myers Squibb, roughly flat from $157.0 million in the prior quarter.
- Over five years, Land & Improvements peaked at $157.0 million in Q4 2025 and troughed at $157.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 157.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 157.00 Mn |
| Mar 31, 2026 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |